Gland Pharma Limited (NSE: GLAND), an injectable-focused pharmaceutical company, announced its financial results for the first quarter and year ended June 30th, 2026. Commenting on the results, Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong start to FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B business model. Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix. We continue to strengthen our growth platform through a robust CDMO pipeline including investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth.”

Financial Highlights

The consolidated financial performance for Q1 FY27 showed significant growth across various metrics:

• Quarterly revenue increased by 20% year-on-year.

• Quarterly R&D investments stood at ₹ 772 million.

• Quarterly adj. EBITDA increased by 37% year-on-year.

• Quarterly adj. EBITDA margin stood at 28%.

• Quarterly PAT increased by 47% year-on-year.

• Quarterly PAT margin increased by ~330 bps year-on-year.

Business Segment Performance

The company’s business segments also performed strongly:

• CDMO business contributed 50% of revenues and grew by 20% year-on-year in Q1FY27.

• B2B* business contributed 50% of revenues and grew by 19% year-on-year in Q1FY27. Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.

As the company continues to leverage its strategic initiatives, it is well-positioned for continued growth and success in the upcoming quarters.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 36.6% over three months and trades near its 52-week highs. The PEG stands at 4.24 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue grows at 21.4% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. The stock trades at 97% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 21.4% and profits at 9.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.24 premium is usually justified. Check Fundamentals of Gland Pharma Limited.

Gland Pharma Limited (NSE: GLAND) announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets. This partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. The collaboration follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.

Comprehensive ‘One-Stop’ Solution

Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality, and regulatory support to provide a comprehensive ‘one-stop’ solution to its partner. The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with the scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million.

Strategic Milestone

The partnership represents an important milestone in Gland Pharma’s growth journey and further strengthens its position as a trusted global CDMO partner for pharmaceutical companies seeking a full-service model including integrated development, technology transfer, and manufacturing solutions for sterile injectable products. Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said: “We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma’s development, technology transfer, manufacturing, and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth. We remain committed to investing in the capabilities and capacity required to support our partner’s evolving needs and ensure reliable supply to patients worldwide.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 36.6% over three months and trades near its 52-week highs. The PEG stands at 4.24 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue grows at 21.4% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. The stock trades at 97% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 21.4% and profits at 9.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.24 premium is usually justified. Check Fundamentals of Gland Pharma Limited.

Gland Pharma Limited (GLAND) has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BRIDION® Injection of Merck Sharp & Dohme LLC. The Product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.

Market Potential

According to IQVIA, the product had US sales of approximately USD 1.6 billion for the twelve months ending April 2026. This approval marks a significant milestone for GLAND, as it expands its injectable portfolio and enters a lucrative market segment.

Company’s Growth

Gland Pharma Limited, established in 1978 in Hyderabad, has grown from a contract manufacturer to one of the largest injectable-focused companies globally. With a presence in over 60 countries, the company has an excellent track record in developing, manufacturing, and marketing sterile injectables. The recent approval is a testament to its continued innovation and market leadership.

As a result, GLAND is well-positioned to capitalize on the growing demand for high-quality, cost-effective injectables in the US and other international markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 39.6% over three months and trades near its 52-week highs. The PEG reaches 3.98. The stock trades on brand and index weight, not on growth. Revenue grows at 21.4% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 21.4% and profits at 9.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 3.98 premium is usually justified. Check Fundamentals of Gland Pharma Limited.